CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 89-98

  Ma, Hong ^a,b   Qazi, Sanjive ^c   Ozer, Zahide ^b   Gaynon, Paul ^a,b   Reaman, Gregory H ^d   Uckun, Fatih M ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

^c GUSTAVUS ADOLPHUS COLLEGE   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Acute lymphoblastic leukaemia; Leukaemia; Mutation; Signalling; Splicing

Indexed keywords

CD22 ANTIGEN; TRANSCRIPTOME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CD22 GENE; CHILD; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; EVENT FREE SURVIVAL; EXON; GENE; GENE DELETION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DISORDER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PEDIATRIC B LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA; PRESCHOOL CHILD; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; THERAPY REFRACTORY CLONE; WESTERN BLOTTING;

ANTIGENS, CD22; BASE SEQUENCE; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; EXONS; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INFANT; INTRONS; NUCLEIC ACID CONFORMATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE; RNA PRECURSORS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 83555173436     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08901.x     Document Type: Article

References (18)

1. Bailey, L.C., Lange, B.J., Rheinhold, S.R. & Bunin, N.J. (2008) Bone marrow relapse in paediatric acute lymphoblastic leukemia. The Lancet Oncology, 9, 873-883.
2. Bao, G., Rhee, W.J. & Tsourkas, A. (2009) Fluorescent probes for live-cell RNA detection. Annual Review of Biomedical Engineering, 11, 25-47.
3. Baralle, D. & Baralle, M. (2005) Splicing in action: assessing disease causing sequence changes. Journal of Medical Genetics, 42, 737-748.
4. Bhojwani, D., Kang, H., Moskowitz, M., Min, D.J., Lee, H., Potter, J., Davidson, G., Willman, C., Borowitz, M., Belitskaya-Levy, I., Hunger, S.P., Raetz, E. & Carroll, W.L. (2006) Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. Blood, 108, 711-717.
5. Buratti, E. & Baralle, D. (2010) Novel roles of U1 snRNP in alternative splicing regulation. RNA Biology, 7, 412-419.
6. Cornall, R.J., Cyster, J.G., Hibbs, M.L., Dunn, A.R., Otipoby, K.L., Clark, E.A. & Goodnow, C.C. (1998) Polygenic autoimmune traits: Lyn, CD22 and SHP-1 are limiting elements of a biochemical pathway regulating BCR signaling and selection. Immunity, 8, 497-508.
7. Gaynon, P.S., Harris, R.E., Altman, A.J., Bostrom, B.C., Breneman, J.C., Hawks, R., Steele, D., Zip, T., Stram, D.O., Villaluna, D. & Trigg, M.E. (2006) Bone Marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and Bone marrow relapse within 12months of the completion of primary Therapy: Children's Oncology Group Study CCG-1941. Journal of Clinical Oncology, 24, 3150-3156.
8. Goraczniak, R., Behlke, M.A. & Gunderson, S.I. (2009) Gene silencing by synthetic U1 adaptors. Nature Biotechnology, 27, 257-263. doi:.
9. Malempati, S., Gaynon, P., Sather, H., La, M.K., Stork, L.C. & Children's Oncology Group. (2007) Outcome after relapse among children with standard-risk acute lymphoblastic Leukemia: Children's Oncology Group (CCG- 1952). Journal of Clinical Oncology, 25, 5800-5807.
10. O'Keefe, T.L., Williams, G.T., Davies, S.L. & Neuberger, M.S. (1996) Hyperresponsive B cells in CD22-deficient mice. Science, 274, 798-801.
11. Reich, M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P. & Mesirov, J.P. (2006) GenePattern 2.0. Nature Genetics, 38, 500-501.
12. Roy, A., Cargill, A., Love, S., Moorman, A.V., Stoneham, S., Lim, A., Darbyshire, P.J., Lancaster, D., Hann, I., Eden, T. & Saha, V. (2005) Outcome after first relapse in childhood acute lymphoblastic leukemia - lessons from the United Kingdom R2 trial. British Journal Haematology, 130, 67-75.
13. Staal, F.J., de Ridder, D., Szczepanski, T., Schonewille, T., van der Linden, E.C., van Wering, E.R., van der Velden, V.H. & van Dongen, J.J. (2010) Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype. Leukemia, 24, 491-499.
14. Tedder, T.F., Poe, J.C. & Haas, K.M. (2005) CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Advances in Immunology, 88, 1-50.
15. Uckun, F.M., Goodman, P., Ma, H., Dibirdik, I. & Qazi, S. (2010a) CD22 Exon 12 Deletion as a Novel Pathogenic Mechanism of Human B-Precursor Leukemia. Proceedings of the National Academy of Sciences of the United States of America, 107, 16852-16857.
16. Uckun, F.M., Qazi, S., Ma, H., Tuel-Ahlgren, L. & Ozer, Z. (2010b) STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America, 107, 2902-2907.
17. Uckun, F.M., Pitt, J. & Qazi, S. (2011) JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia. Expert Review of Anticancer Therapy, 11, 37-48.
18. Venables, J.P. (2004) Aberrant and alternative splicing in cancer. Cancer Research, 64, 7647-7654.